MONTREAL, March 30 / PRNewswire / – Montreal Heart Institute (MHI) has
Today are the results of his study COLchicine Cardiovascular Outlook
Trial (COLCOT) announced. In this crucial study was
the effect of colchicine in the prevention of ischemic
Cardiovascular disease in patients with recent
Heart attack (MI), which received standard treatment.
In this study, patients received daily in addition
Standard treatment received 0.5 mg of colchicine, a lower rate
first and recurrent ischemic cardiovascular disease
compared to patients who received standard treatment only.
These data were reported simultaneously in the New England Journal of Medicine (NEJM).
published today at a scientific session of American Heart
Association (AHA) presented.
Pharmascience Inc. is proud to be part of this innovative clinic
Study whose results have been significantly positive
Effects on cardiovascular outcomes in patients and patients
public health in general. It was shown
that inflammation in cardiovascular disease plays an important role
gigs and the results from COLCOT represent a lot
Significant progress in linking the reduction of
Inflammation after myocardial infarction with improved
An important aspect of the COLCOT study is that it is a new one
The use of colchicine enables a drug that has been used
Decades for the treatment of gout and familial Mediterranean fever
used. The new use of older and established drugs
means finding additional uses for medicines such as
has already been approved.
"Pharmascience has decided to innovate in
to support medical treatment like COLCOT here in Canada.
Our goal is to promote therapeutic innovation and
Improving the results of patients with a new indication
for an old proven drug that is affordable
can be, "says Dr. David Goodman, CEO of Pharmascience.
"We are convinced that these projects are perfect for ours
Want fit, through responsible entrepreneurship
contribute to therapeutic progress. "
The clinical use of colchicine is supported by the fact that
The security profile is well known and compared to some
newer cardiovascular drugs for similar indications much
is affordable. Generics with new use make attractive
and cost-effective options for public and private programs
Reimbursement of drugs in connection with ongoing problems with
the benefits of new drugs.
"Unfortunately, only a few pharmaceutical companies follow this path
There are inherent financial barriers, "Dr. Goodman added.
"There is no guarantee that the extra expenditure on research
and development for new use of drugs
arise, come back in, for in the field of generic medicine, the intellectual property
not protected. Pharmascience is for the social
Benefits ready to take this risk. But we need to
Assisting drug administration authorities and managers
for approval and repayment, which the new use does not
brakes, but instead replaces innovation. "
INFORMATION ON PHARMASCIENCE INC.
Founded in 1983, Pharmascience Inc. has 1,500 employees
Employees are the largest employer in the pharmacy sector in Qebec
and headquarters in Montreal. Pharmascience Inc. is one
Privately owned pharmaceutical company that covers the full range of
Offers services and is anchored in Canada. With sales in
more than 60 countries are growing their global presence. With investments of
more than $ 43 million in 2018, Pharmascience Inc.
Ranked 56 among the largest 100 Canadian investors in research and research
Development and is the fourth largest manufacturer of generic drugs in the country.
Pharmascience Inc. has stated values based on the importance of
Investments in employees and young people are based. the
The company provides through a series of programs and initiatives for
their personal development and life. 2019 received Pharmascience
Inc. as part of Canada's Top 100 Employers project
Recognition for his investments through the election in the group of
Canada's best employer for young people and was named one
was named the best employer in Montreal. In 2018, it was ranked
the prestigious Forbes Pharmascience Inc. magazine in its list of
Top 300 employers.
Shares on the radar: Valneva . Warimpex . Polytec . Addiko Bank . Telecom Austria . FACC . Rosgix . Mayr-Melnhof . Semperit . RBI . voestalpine . AT&S . SW environmental technology . UBM ,
Novomatic Group is the manufacturer and operator of one of the largest gaming technology companies in the world and has more than 25,000 employees. The Group operates in 45 countries and exports innovative gaming equipment, system solutions, lottery system solutions and services to more than 70 countries.
>> Visit 52 other partners at boerse-social.com/partner
More updated OTS messages HERE